TN2015000175A1 - Heteroaryl substituted pyridyl compounds useful as kinase modulators - Google Patents
Heteroaryl substituted pyridyl compounds useful as kinase modulatorsInfo
- Publication number
- TN2015000175A1 TN2015000175A1 TNP2015000175A TN2015000175A TN2015000175A1 TN 2015000175 A1 TN2015000175 A1 TN 2015000175A1 TN P2015000175 A TNP2015000175 A TN P2015000175A TN 2015000175 A TN2015000175 A TN 2015000175A TN 2015000175 A1 TN2015000175 A1 TN 2015000175A1
- Authority
- TN
- Tunisia
- Prior art keywords
- compounds useful
- kinase modulators
- heteroaryl substituted
- substituted pyridyl
- pyridyl compounds
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 title abstract 2
- 102000020233 phosphotransferase Human genes 0.000 title abstract 2
- 125000004076 pyridyl group Chemical group 0.000 title 1
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 abstract 1
- 101710199010 Interleukin-1 receptor-associated kinase 4 Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261723848P | 2012-11-08 | 2012-11-08 | |
| US201361774824P | 2013-03-08 | 2013-03-08 | |
| PCT/US2013/068875 WO2014074675A1 (fr) | 2012-11-08 | 2013-11-07 | Composés pyridyle à substitution hétéroaryle utiles en tant que modulateurs de kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2015000175A1 true TN2015000175A1 (en) | 2016-10-03 |
Family
ID=49667571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2015000175A TN2015000175A1 (en) | 2012-11-08 | 2015-05-07 | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US9657009B2 (fr) |
| EP (1) | EP2917206B1 (fr) |
| JP (1) | JP6204484B2 (fr) |
| KR (1) | KR20150079963A (fr) |
| CN (1) | CN104781254B (fr) |
| AU (1) | AU2013341200A1 (fr) |
| BR (1) | BR112015009850A2 (fr) |
| CA (1) | CA2890983A1 (fr) |
| CL (1) | CL2015001249A1 (fr) |
| CO (1) | CO7400871A2 (fr) |
| EA (1) | EA024940B1 (fr) |
| ES (1) | ES2615302T3 (fr) |
| HK (1) | HK1213895A1 (fr) |
| IL (1) | IL238609A0 (fr) |
| MX (1) | MX2015005562A (fr) |
| PE (1) | PE20150953A1 (fr) |
| PH (1) | PH12015501005A1 (fr) |
| SG (1) | SG11201503397YA (fr) |
| TN (1) | TN2015000175A1 (fr) |
| TW (1) | TW201427953A (fr) |
| WO (1) | WO2014074675A1 (fr) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6215338B2 (ja) | 2012-11-08 | 2017-10-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 |
| SG11201503397YA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| AP2015008510A0 (en) | 2012-12-21 | 2015-06-30 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
| NO2865735T3 (fr) | 2013-07-12 | 2018-07-21 | ||
| TW201609693A (zh) * | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| TWI677489B (zh) | 2014-06-20 | 2019-11-21 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
| NO2717902T3 (fr) | 2014-06-20 | 2018-06-23 | ||
| TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
| AR105114A1 (es) * | 2015-06-24 | 2017-09-06 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituida con heteroarilo |
| UY36749A (es) | 2015-06-24 | 2016-12-30 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Compuestos de aminopiridina sustituida con heteroarilo como inhibidores de quinasa y moduladores de irak-4, y composiciones farmacéuticas que los contienen |
| TW201718571A (zh) | 2015-06-24 | 2017-06-01 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| KR102088157B1 (ko) | 2015-09-02 | 2020-03-12 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 브로모도메인 억제제로서 사용하기 위한 피리디논 디카복스아미드 |
| RU2018112312A (ru) | 2015-09-22 | 2019-10-23 | ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед | Пиридинондикарбоксамиды для применения в качестве ингибиторов бромодомена |
| KR20180059551A (ko) | 2015-10-05 | 2018-06-04 | 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 | 브로모도메인 억제제로서 2-옥소-1,2-디하이드로피리딘-3,5-디카복스아미드 화합물 |
| US10570096B2 (en) * | 2015-11-26 | 2020-02-25 | Novartis Ag | Diamino pyridine derivatives |
| EP3440069B1 (fr) | 2016-04-07 | 2020-10-28 | GlaxoSmithKline Intellectual Property (No. 2) Limited | Dérivés de pyridyle en tant qu'inhibiteurs de bromodomaines |
| EP3464242A1 (fr) * | 2016-05-24 | 2019-04-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Dérivés de pyridine dicarboxamide utilisés comme inhibiteurs de bromodomaine |
| JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
| GB201703282D0 (en) | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
| JOP20190192A1 (ar) | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | مشتقات بيرازول بوصفها مثبطات برومودومين |
| KR102604900B1 (ko) | 2017-05-11 | 2023-11-21 | 브리스톨-마이어스 스큅 컴퍼니 | Irak4 억제제로서 유용한 티에노피리딘 및 벤조티오펜 |
| JP2020524691A (ja) | 2017-06-21 | 2020-08-20 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＩＲＡＫ４調節因子としてのピラゾロ［１，５ａ］ピリミジン誘導体 |
| EP3642201A1 (fr) | 2017-06-21 | 2020-04-29 | H. Hoffnabb-La Roche Ag | Dérivés d'isoindolinone utilisés en tant que modulateurs d'irak4 |
| EP3684366A4 (fr) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Ligands crbn et utilisations de ces derniers |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| WO2019111218A1 (fr) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs d'irak4 |
| IL315310A (en) * | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737675A4 (fr) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Ligands crbn et leurs utilisations |
| EP3737666A4 (fr) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Agents de dégradation de protéines et utilisations associées |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| US12454520B2 (en) | 2018-07-06 | 2025-10-28 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| WO2020051571A1 (fr) * | 2018-09-07 | 2020-03-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Inhibiteurs de brd4-jak2 |
| US12391676B2 (en) | 2018-09-07 | 2025-08-19 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | BRD4-JAK2 inhibitors |
| BR112021010484A2 (pt) | 2018-11-30 | 2021-08-24 | Kymera Therapeutics, Inc. | Degradadores de irak e usos dos mesmos |
| JP7570399B2 (ja) | 2019-07-18 | 2024-10-21 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用な三環式ヘテロアリール化合物 |
| EP3999512B1 (fr) | 2019-07-18 | 2023-08-23 | Bristol-Myers Squibb Company | Composés pyrazolo [3,4-d] pyrrolo [1,2-b] pyridazinyle utiles en tant qu'inhibiteurs de l'irak4 |
| EP4004000B1 (fr) * | 2019-07-23 | 2025-07-09 | Bristol-Myers Squibb Company | Composés thiénopyridinyles et thioazopyridinyles en tant qu'inhibiteurs d'irak 4 |
| EP4010317B1 (fr) | 2019-08-06 | 2024-06-19 | Bristol-Myers Squibb Company | Composés bicycliques hétérocycliques comme inhibiteurs de la irak4 |
| CN114206874B (zh) * | 2019-08-13 | 2024-08-02 | 百时美施贵宝公司 | 可用作irak4抑制剂的双环杂芳基化合物 |
| WO2021127283A2 (fr) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
| CN115052627A (zh) | 2019-12-17 | 2022-09-13 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| CN115135642B (zh) | 2019-12-23 | 2025-03-04 | 缆图药品公司 | Egfr突变形式的抑制剂 |
| CN115335380B (zh) * | 2020-02-03 | 2024-08-02 | 百时美施贵宝公司 | 可用作irak4抑制剂的三环杂芳基化合物 |
| US12391702B2 (en) | 2020-02-03 | 2025-08-19 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as IRAK4 inhibitors |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| WO2022133046A2 (fr) * | 2020-12-16 | 2022-06-23 | Ifm Due, Inc. | Composés et compositions pour traiter des états pathologiques associés à une activité de sting |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| AU2022220043A1 (en) | 2021-02-15 | 2023-08-31 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| CA3207380A1 (fr) | 2021-02-15 | 2022-08-18 | Haojing RONG | Agents de degradation d'irak4 et leurs utilisations |
| IL308314A (en) | 2021-05-07 | 2024-01-01 | Kymera Therapeutics Inc | CDK2 compounds and their uses |
| WO2023076556A1 (fr) | 2021-10-29 | 2023-05-04 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak4 et leur synthèse |
| US20250025465A1 (en) * | 2021-11-17 | 2025-01-23 | Northwestern University | Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma |
| WO2023147594A2 (fr) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Agents de dégradation d'irak et leurs utilisations |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002102800A1 (fr) | 2001-06-15 | 2002-12-27 | Vertex Pharmaceuticals Incorporated | 5-(2-aminopyrimidine-4-yl) benzisoxazoles en tant qu'inhibiteurs de proteine kinases |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| US7449456B2 (en) | 2002-06-28 | 2008-11-11 | Astellas Pharma, Inc. | Diaminopyrimidinecarboxamide derivative |
| ATE433967T1 (de) | 2003-01-17 | 2009-07-15 | Warner Lambert Co | 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation |
| CN1820001A (zh) | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经取代的杂环二芳基胺类似物 |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| RU2471793C2 (ru) | 2007-06-08 | 2013-01-10 | Байер Кропсайенс Аг | Фунгицид на основе гетероциклил-пиримидинил-аминопроизводных |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| WO2009046416A1 (fr) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines en tant qu'inhibiteurs de kinases jak |
| EP2070924A1 (fr) * | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Nouveaux dérivés de 2-hetarylthiazol-4-amides d'acide carboxylique, leur fabrication et leur utilisation en tant que médicament |
| JP5542692B2 (ja) | 2008-11-28 | 2014-07-09 | 興和株式会社 | ピリジン−３−カルボキシアミド誘導体 |
| WO2010144647A1 (fr) | 2009-06-12 | 2010-12-16 | Bristol-Myers Squibb Company | Composés de nicotinamide utiles en tant que modulateurs de kinases |
| CA2778979C (fr) | 2009-10-30 | 2018-04-24 | Janssen Pharmaceutica Nv | Pyrimidines phenoxy-substituees utilisees comme modulateurs des recepteurs aux opioides |
| EP2532656A1 (fr) | 2010-02-01 | 2012-12-12 | Nippon Chemiphar Co., Ltd. | Agoniste du gpr119 |
| KR20130016244A (ko) | 2010-03-10 | 2013-02-14 | 인게니움 파르마코이티칼스 게엠베하 | 단백질 키나아제의 억제제 |
| AU2012249240A1 (en) | 2011-04-29 | 2013-11-07 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitors |
| JP6096807B2 (ja) | 2012-01-13 | 2017-03-15 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | キナーゼ阻害剤として有用なトリアゾリル置換されたピリジル化合物 |
| EP2802579B1 (fr) | 2012-01-13 | 2016-04-13 | Bristol-Myers Squibb Company | Composés pyridyles substitués par thiazolyl ou thiadiazolyl utiles en tant qu'inhibiteurs de kinase |
| ES2686500T3 (es) | 2012-01-13 | 2018-10-18 | Bristol-Myers Squibb Company | Compuestos de piridilo sustituidos con heterocíclicos, útiles como inhibidores de cinasas |
| EP2922841B8 (fr) * | 2012-11-08 | 2017-08-02 | Bristol-Myers Squibb Company | Composés pyridyle substitués par alkyl-amide, utiles comme modulateurs d'il-12, il-23 et/ou de réponses à l'ifn alpha |
| SG11201503397YA (en) | 2012-11-08 | 2015-05-28 | Bristol Myers Squibb Co | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
| TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
-
2013
- 2013-11-07 SG SG11201503397YA patent/SG11201503397YA/en unknown
- 2013-11-07 EP EP13795914.4A patent/EP2917206B1/fr not_active Not-in-force
- 2013-11-07 EA EA201590920A patent/EA024940B1/ru not_active IP Right Cessation
- 2013-11-07 JP JP2015541886A patent/JP6204484B2/ja not_active Expired - Fee Related
- 2013-11-07 HK HK16101951.7A patent/HK1213895A1/zh unknown
- 2013-11-07 BR BR112015009850A patent/BR112015009850A2/pt not_active IP Right Cessation
- 2013-11-07 ES ES13795914.4T patent/ES2615302T3/es active Active
- 2013-11-07 KR KR1020157014808A patent/KR20150079963A/ko not_active Withdrawn
- 2013-11-07 MX MX2015005562A patent/MX2015005562A/es unknown
- 2013-11-07 CA CA2890983A patent/CA2890983A1/fr not_active Abandoned
- 2013-11-07 WO PCT/US2013/068875 patent/WO2014074675A1/fr not_active Ceased
- 2013-11-07 TW TW102140575A patent/TW201427953A/zh unknown
- 2013-11-07 AU AU2013341200A patent/AU2013341200A1/en not_active Abandoned
- 2013-11-07 US US14/441,705 patent/US9657009B2/en active Active
- 2013-11-07 CN CN201380058618.7A patent/CN104781254B/zh not_active Expired - Fee Related
- 2013-11-07 PE PE2015000613A patent/PE20150953A1/es not_active Application Discontinuation
-
2015
- 2015-05-04 IL IL238609A patent/IL238609A0/en unknown
- 2015-05-06 PH PH12015501005A patent/PH12015501005A1/en unknown
- 2015-05-07 TN TNP2015000175A patent/TN2015000175A1/fr unknown
- 2015-05-08 CL CL2015001249A patent/CL2015001249A1/es unknown
- 2015-06-03 CO CO15127843A patent/CO7400871A2/es unknown
-
2017
- 2017-04-06 US US15/480,682 patent/US10023562B2/en active Active
-
2018
- 2018-06-15 US US16/009,389 patent/US10544133B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2615302T3 (es) | 2017-06-06 |
| CN104781254A (zh) | 2015-07-15 |
| JP2016501186A (ja) | 2016-01-18 |
| WO2014074675A1 (fr) | 2014-05-15 |
| EA024940B1 (ru) | 2016-11-30 |
| EP2917206A1 (fr) | 2015-09-16 |
| US10023562B2 (en) | 2018-07-17 |
| AU2013341200A1 (en) | 2015-07-02 |
| TW201427953A (zh) | 2014-07-16 |
| MX2015005562A (es) | 2015-07-23 |
| SG11201503397YA (en) | 2015-05-28 |
| KR20150079963A (ko) | 2015-07-08 |
| CN104781254B (zh) | 2016-12-14 |
| CA2890983A1 (fr) | 2014-05-15 |
| US20150284382A1 (en) | 2015-10-08 |
| EP2917206B1 (fr) | 2016-12-21 |
| JP6204484B2 (ja) | 2017-09-27 |
| CO7400871A2 (es) | 2015-09-30 |
| IL238609A0 (en) | 2015-06-30 |
| BR112015009850A2 (pt) | 2017-07-11 |
| US10544133B2 (en) | 2020-01-28 |
| HK1213895A1 (zh) | 2016-07-15 |
| EA201590920A1 (ru) | 2015-09-30 |
| US9657009B2 (en) | 2017-05-23 |
| CL2015001249A1 (es) | 2015-07-31 |
| PE20150953A1 (es) | 2015-06-20 |
| PH12015501005A1 (en) | 2015-07-27 |
| US20170210730A1 (en) | 2017-07-27 |
| US20180370956A1 (en) | 2018-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2015000175A1 (en) | Heteroaryl substituted pyridyl compounds useful as kinase modulators | |
| PH12018500342A1 (en) | Heterocyclic amides as kinase inhibitors | |
| PH12015502031B1 (en) | Tetrahydropyrrolothiazine compounds | |
| MX2015002040A (es) | Baricitinib deuterado. | |
| IN2015DN00598A (fr) | ||
| MY171055A (en) | 3,5-disubstituted alkynylbenzene compound and salt thereof | |
| MY194668A (en) | Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses | |
| MX2016005853A (es) | Compuestos de piridilo sustituidos con alquilamida utiles como muduladores de respuestas de citocinas heterodimericas interleucina 12 y 23 (il-12 e il-23) y/o interferon alfa (ifnalfa). | |
| PH12016500225B1 (en) | Novel quinoline-substituted compound | |
| IN2012DE00621A (fr) | ||
| JO3318B1 (ar) | مثبطات bace | |
| IN2012DE00620A (fr) | ||
| MX2015008829A (es) | Momelotinib deuterado. | |
| EA201591915A1 (ru) | Соединения феноксиэтил дигидро-1h-изохинолина | |
| EA201892449A1 (ru) | Конденсированные гетероциклические соединения | |
| UA113086C2 (xx) | Піразольні сполуки як інгібітори sglt1 | |
| MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
| MX2015007309A (es) | Derivado de hidantoina. | |
| MX2016006807A (es) | Derivados de imidazol. | |
| MX2015012610A (es) | Pacritinib deuterizado. | |
| WO2015044960A3 (fr) | Composés pour l'inhibition de la croissance cellulaire non régulée | |
| IN2012DE00110A (fr) | ||
| UA86566U (en) | N-hydroxyhomoazaadamantanone and dioxomolybdenum complex thereof | |
| MX2018011117A (es) | Forma cristalina. | |
| UA87695U (uk) | Сполука 4,5,6,7-тетрагідро-3н-2-n-(пара-метоксифенациламіно)-азепіну гідрохлорид, що має інотропну активність |